secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001171843-25-001678
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences simufilam Phase 3 trial fails all endpoints; Alzheimer's program discontinued
--------------------------------------------------------------------------------

- Phase 3 REFOCUS-ALZ failed all co-primary, secondary, and biomarker endpoints.
- Simufilam showed no significant difference vs placebo on ADAS-COG12 or ADCS-ADL; p-values 0.37-0.67 and 0.16-0.23.
- Cassava will discontinue all simufilam Alzheimer's development by Q2 2025.
- Company had $128.6M cash at Dec 31, 2024; exploring TSC-related epilepsy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325001678/0001171843-25-001678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325001678/f8k_032525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer